NCT00858078

A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women

Completed Last updated 30 November 2021

What this trial tests

trial in BRCA1 Gene in 76 participants. Completed in 3 April 2015.

Timeline

21 June 2011

Primary endpoint
13 March 2015

3 April 2015

Quick facts

Lead sponsor	National Cancer Institute (NCI)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	76
Start date	21 June 2011
Primary completion	13 March 2015
Estimated completion	3 April 2015
Sites	1 location across United States

Conditions studied

• BRCA1 Gene — all drugs for BRCA1 Gene →
• BRCA2 Gene — all drugs for BRCA2 Gene →

Sponsor

National Cancer Institute (NCI)

Who can join

Adults 18 to 100, female only, with BRCA1 Gene or BRCA2 Gene. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:

* Mutations detected in the BRCA1 or BRCA2 genes have been show to produce very high risks of breast and ovarian cancer (as high as 90% and 60%, respectively), as well as accompanying risks for several other types of cancer. Women who have these genetic anomalies and who do not have cancer are aware of their high-risk status, which can have an effect on their ability to make decisions about personal choices and health care.
* Researchers are interested in learning more about how people who know their cancer risk status make decisions on personal relationships, family formation, and risk-reduction options.

Objectives:

\- To study young women s experiences and decision-making processes regarding family history, genetic testing, couple relationships, family formation, and cancer risk management within the context of their experiences as BRCA1/2 mutation carriers.

Eligibility:

* Women between the ages of 18 and 35 years of age and older who have been identified as having a BRCA1 or BRCA2 mutation. Participants must be contemplating or have experienced couple relationships, family formation, and/or risk management and reduction.
* Participants must be willing to have their interviews digitally recorded

Design:

* Researchers will conduct between 30 and 50 telephone interviews of study participants. Each interview will be approximately 90 minutes in length. The interview consists of open-ended questions that ask about the participants and their experiences before, during, and after they underwent genetic testing for BRCA1/2.
* At least one focus group will be coordinated at a national conference for individuals who are aware of their genetically based cancer risk. If more than 25 individuals are interested in participating in the group, an additional focus group will be convened.
* No medical treatments are specifically offered as a part of this study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.